Fluorine-19 MRI Contrast Agents for Cell Tracking and Lung Imaging

Supplementary Issue: New Concepts in Magnetic Resonance as Applied to Cellular and In Vivo Applications

Matthew S. Fox1,2, Jeffrey M. Gaudet1,2 and Paula J. Foster1,2

1Department of Medical Biophysics, University of Western Ontario, London, ON, Canada. 2Imaging Research Laboratories, Robarts Research Institute, London, ON, Canada.

ABSTRACT: Fluorine-19 (19F)-based contrast agents for magnetic resonance imaging stand to revolutionize imaging-based research and clinical trials in several fields of medical intervention. First, their use in characterizing in vivo cell behavior may help bring cellular therapy closer to clinical acceptance. Second, their use in lung imaging provides novel noninvasive interrogation of the ventilated airspaces without the need for complicated, hard-to-distribute hardware. This article reviews the current state of 19F-based cell tracking and lung imaging using magnetic resonance imaging and describes the link between the methods across these fields and how they may mutually benefit from solutions to mutual problems encountered when imaging 19F-containing compounds, as well as hardware and software advancements.

KEYWORDS: fluorine-19, cellular therapy, cell tracking, lung imaging, MRI, isoflurane

SUPPLEMENT: New Concepts in Magnetic Resonance as Applied to Cellular and In Vivo Applications

CITATION: Fox et al. Fluorine-19 MRI Contrast Agents for Cell Tracking and Lung Imaging. Magnetic Resonance Insights 2015:8(51) 53–67 doi:10.4137/MRI.S23559.

TYPE: Review

RECEIVED: October 23, 2015. RESUBMITTED: January 24, 2016. ACCEPTED FOR PUBLICATION: January 31, 2016.

ACADEMIC EDITOR: Sendhil Velan, Editor in Chief

PEER REVIEW: Four peer reviewers contributed to the peer review report. Reviewers’ reports totaled 2180 words, excluding any confidential comments to the academic editor.

FUNDING: Authors disclose no external funding sources.

COMPETING INTERESTS: Authors disclose no potential conflicts of interest.

COPYRIGHT: © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

CORRESPONDENCE: matthew.s.fox.4@gmail.com

Paper subject to independent expert single-blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Published by Libertas Academica. Learn more about this journal.

Introduction

Fluorine-19 (19F) has the potential to revolutionize imaging-based cell tracking, lung imaging, and drug development by enabling alternate routes for clinical translation of these techniques to patients. 19F is a versatile and nuclear magnetic resonance (NMR) active nucleus. Observations were originally attempted in 1942 using NMR1 and later with magnetic resonance imaging (MRI) in the 1970s,2 when numerous applications were surmised. 19F T1 relaxation rates were first used in the early 1990s to determine the intracellular partial pressure of oxygen, but direct fluorine imaging still proved elusive.3 Technology has caught up with the predictions of the past and MRI contrast agents containing 19F are now at the forefront of imaging research in a variety of biomedical fields such as cell tracking, lung imaging and drug development. Figure 1 clearly demonstrates an increase in the number of publications for 19F-based MRI cell tracking within the past decade. From an MRI point of view, 19F is part of the family of nonproton nuclei (or X-nuclei). It is 100% naturally abundant and has a spin of 1/2, a gyromagnetic ratio of appreciable size (9.4%, the largest of X-nuclei) compared with protons (3.7%), and sensitivity of 83% relative to 1H. Commonly used fluorinated contrast agents that are used to probe the microbiological and macrobiological environments include perfluorocarbons (PFCs) such as perfluoroxypropylene (PFPE), perfluoro-15-crown-5-ether (PFCE), sulfur hexafluoride (SF6), perfluoropropane (C3F8), and hexafluoroethane (C2F6). Their usage and important physical properties are conveniently summarized in Table 1. Fluorinated contrast agents are used to probe the microbiological environment as cell-labelling agents4 and theranostic drugs and therapies. Therapeutic delivery of labeled cells using PFC emulsions (eg, dendritic cells [DCs]5) or drugs (eg, 5-fluorouracil6) containing 19F can be quantified and tracked noninvasively and longitudinally using MRI. Agents such as fluorinated gases are also useful for probing macromolecular environments such as the airspaces of lungs.6 Inert fluorinated gases containing multiple chemically equivalent 19F atoms per molecule are used in the field of MRI of the lung as inhaled contrast agents to probe lung structure and function noninvasively. This article discusses the role of 19F in the fields of cell tracking and lung imaging. Many new contributions have been reported in the past few years in these fields and their importance will be discussed. Though drug development is a large contributor to the 19F body of literature, its scope is vast, and we direct interested readers to the thorough review on the role of 19F in imaging and drug development by Bartusik and Aebisher.7

Cell Tracking Using Imaging Techniques

Cell tracking is an important tool for the field of cellular therapy. The goals of cellular therapy are to stimulate the immune...
system to elicit an immune response, eg, in cancer patients, and regenerate damaged tissues using stem cells. The requirement and need to track cells noninvasively is of great importance for the development of cellular therapies and vaccines for eventual clinical translation and acceptance. Therefore, cell tracking is a necessary tool in order to help answer the questions: How many cells were actually transplanted? How long do transplanted cells survive? Do transplanted cells migrate and reach their therapeutic targets? Though theory can help predict the status of cells and routes of migration, in practice, the outcomes are often very different and patient specific, which is why methods of noninvasive imaging are needed. Previously developed cell-tracking techniques employed the use of fluorescent labels, radio labels, iron labels, and combinations of these for dual-mode identification (eg, iron with fluorescent tags), but all of these techniques have restrictions on clinical feasibility, which will be described in the following sections. Fluorinated contrast agents have emerged as a recent addition to these techniques in the form of PFC emulsions and other fluorinated compounds.

It is important for any cell-labelling strategy that the substances used as labelling agents do not alter the properties of cells, do not cause cytotoxic effects to the cells, and do not change their phenotype or behavior. Using fluorescence-activated cell sorting (FACS), consistency of cell phenotype can be verified aiding in a novel label development. Simple assays using trypan blue can be used to compare cell viability with and without label to reveal any negative cytotoxic effects of the label on therapeutic cells. Practical issues arising from cell label retention are cell division, cell death, and the potential for bystander cells to adopt labels. Cell division leads to a dilution of contrast agent content per cell, reducing their individual detectability for highly localized labeled cells. Upon cell death, the label is free to leak out from the cells and become dispersed. Bystander cells may phagocytose the recently released label from dead cells and contribute to false-positive results. Important clinical translation considerations include the safety profile of the labelling agents, whether there are any toxic effects, and how the labels are metabolized and cleared from the body (biological half-life) once they leave the cells they initially resided in.

Nonfluorinated Cell-Tracking Methods
Previously developed cell-tracking methods include the use of fluorescence microscopy, positron emission tomography (PET) using radioactive agents to label cells, and MRI using heavy metal contrast agents (eg, superparamagnetic iron oxide [SPIO], Gd). Fluorescence microscopy using fluorescently tagged cells has the ability to reveal tagged cells in organs with enough resolution and signal-to-noise ratio (SNR) to resolve even single cells. However, the ability to observe cells in vivo using these methods becomes difficult as tissue depth increases, limiting in vivo studies to small animals. A thorough review of fluorescence molecular imaging can be found here.\(^4\)
The use of radio labels in single-photon emission computed tomography (SPECT) and PET provides high sensitivity and has been used for cell-tracking applications. There are some significant drawbacks to these techniques, which include the following: their radioactive nature, which imparts ionizing radiation to cells and tissues, resulting in potential cytotoxicity to the cells they label; relatively short nuclear half-lives, limiting the effectiveness for longitudinal studies; and limited spatial resolution. However, the latter may be overcome by recent developments in modern combined MR/PET or PET/computed tomography (CT) systems to provide improved localization of cells due to high-resolution anatomical imaging from their MR and CT counterparts.

Cell tracking using iron labels was first utilized by Bulte et al and Yeh et al in the early 1990s by internalizing dextran-coated magnetite particles and SPIO particles (Aquamag100 and BMS 180549) within cells and detecting them using MRI. Iron-labeled cells are usually identified by the negative contrast observed in MR images due to their enhancement of $R_2$ and $R_2^*$, though positive contrast methods also exist using methods such as ultrashort echo time (UTE) imaging and sweep imaging with Fourier transformation. These regions of signal voids are of much larger spatial extent than the cells themselves due to local changes in magnetic susceptibility. Small quantities of label can have large detectable effects on the magnetization of surrounding protons making their regional detection easy using MRI. Later developments in methods and technology lead to the ability to detect single cells labeled with iron in vivo using MRI as demonstrated by Heyn et al and Shapiro et al.

**Table 1.** Properties of common $^{19}$F substances used in the fields of cell tracking and lung imaging. Numbers of equivalent atoms (strongest peak) are presented as well as various reported relaxation times and the corresponding field strengths for each substance. Citations are superscripted and known special conditions are subscripted.

| USED IN               | SINGLE PEAK          | $^{19}$F SPINS | $T_1$ (ms) | $T_2$ (ms) | $T_2^*$ (ms) |
|-----------------------|----------------------|----------------|------------|------------|--------------|
| **PFPE**              | Cell tracking        | No             | 28–36      | 3T, 470$^{57}$ | 3T, 250$^{57}$ |
|                       |                      |                |            | 7T, 590$^{56}$ | 7T, 82$^{30}$ |
|                       |                      |                |            | 428$^{30}$ & |              |
|                       |                      |                |            | 9.4T, 510$^{56}$ |              |
|                       |                      |                |            | 437$^{33}$ & |              |
|                       |                      |                |            | 280$^{33}$ & |              |
|                       |                      |                |            | 380$^{33}$ & |              |
|                       |                      |                |            | 14.1T, 400$^{36}$ |              |
|                       |                      |                |            | 11.7T, 153$^{33}$ |              |
|                       |                      |                |            | 68$^{33}$ & |              |
| **PFCE**              | Cell tracking        | Yes            | 20$^{66}$  | 7T, 2500$^{56}$ | 7T, 50$^{41}$ |
|                       |                      |                |            | 950$^{41}$ & |              |
|                       |                      |                |            | 9.4T, 580$^{43}$ |              |
|                       |                      |                |            | 600$^{31}$ & |              |
|                       |                      |                |            | 1000$^{31}$ & |              |
|                       |                      |                |            | 1160$^{10}$ |              |
|                       |                      |                |            | 1350$^{97}$ |              |
|                       |                      |                |            | 1400$^{97}$ |              |
|                       |                      |                |            | 1670$^{56}$ & |              |
|                       |                      |                |            | 11.7T, 800$^{37}$ |              |
|                       |                      |                |            | 14.1T, 1120$^{56}$ |              |
|                       |                      |                |            | 4.7T, 2.7$^{16}$ |              |
| **SF$_6$**            | Lung imaging, ultrasound | Yes       | 6          | 1.5T, 1.2$^{14}$ | 3T, 1.2$^{10}$ |
|                       |                      |                |            | 2$^{124}$ |              |
| **C$_2$F$_6$**        | Lung imaging         | Yes            | 6          | 1.9T, 5.9$^{10}$ | 1.9T, 5.3$^{10}$ |
|                       |                      |                |            | 2$^{124}$ |              |
| **C$_3$F$_8$**        | Lung imaging         | No             | 6          | 1.5T, 18$^{15}$ | 3T, 12.4$^{10}$ |
|                       |                      |                |            | 1.5T, 16$^{15}$ | 3T, 10$^{12}$ |

Notes: $^a$Extrapolated from data at 310K (Kadayakara et al.);$^b$in vivo; $^c$internalized within cells; $^d$emulsion; $^e$neat; $^f$field not reported; $^g$saline; $^h$blood.
Though iron labelling is a powerful tool for longitudinal cell tracking using MRI, quantification of absolute cell numbers is difficult since the correlation between void volume and iron concentration is only linear for small concentrations of internalized iron.\(^{19}\) Furthermore, it can be difficult to discern negative contrast generated by iron with those from natural effects or image artifacts. Several reviews have been published in recent years describing technological and methodological advancements as well as the future of cell tracking using SPIO and \(^{19}\)F-labeled cells.\(^{20–23}\)

**Fluorinated Contrast Agents for Cell Tracking Using MRI**

The use of PFCs for cell tracking using MRI was first demonstrated in 2005 by Ahrens et al describing a complete imaging platform for tracking immunotherapeutic cells.\(^{24}\) PFC-labeled cells provide direct detection of cells in the form of positive-contrast hot-spot density-weighted images\(^{24}\) owing to the inherent lack of \(^{19}\)F background signal in vivo. Furthermore, unlike iron, the use of \(^{19}\)F labels do not distort the local magnetic field enabling the ability to collect complementary high-resolution images of the underlying anatomical structures using \(^1\)H MRI. After registration of images obtained using both nuclei, these images aid in the verification and localization of labeled cells within injection sites or those that have migrated to organs or lymph nodes. Another advantage over iron is that the PFCs detectable signal is directly proportional to the amount of internalized PFC within each cell, enabling quantitative cell tracking.

Labelling of cells using PFCs can be performed using ex vivo methods (cell culture flasks) or in situ as an injection (usually intravenous). For the ex vivo case, cells are incubated at a specific concentration of cells (typically \(2 \times 10^5\) cells/mL) and \(^{19}\)F-containing label within the cell media in order to promote cellular uptake. Uptake is not instantaneous, and there is an optimum label dose and incubation time depending on the agent used and due to natural cell division during the labelling period. Potential cytotoxic effects can occur due to extended exposure to high concentrations of label within the media. This is further complicated by the fact that these optima are different for each cell type of interest. These parameters are important to map out to maximize the cellular uptake of label (which translates to improved SNR within post transplant images) as well as to ensure that the labels do not affect the cells’ behavior (eg, migration, differentiation, and surface marker expression).

One method to increase the available SNR within the cells is to increase the number of \(^{19}\)F spins by means of using larger label particle sizes. However, it has been shown that there is an optimum size where smaller sized particles (<560 nm) do not disrupt cell behavior.\(^{25}\) Labelling cells ex vivo is a very powerful technique owing to the ability to label specific cells in controlled conditions with the potential to quantify absolute counts of cells.

Cell labelling in situ is more straightforward but less target specific and lacks the potential to quantify cell numbers absolutely. To label cells in situ, an injectable PFC emulsion is formulated and administered intravenously. While within the vascular system, circulating cells (monocytes, macrophages, etc.) phagocytose the label and become PFC-labeled cells. Cells labeled this way usually consist of a distribution of cell types possessing variable label concentration. This technique is often used to label the influx of inflammatory macrophages responding to a recent insult.\(^{26–31}\)

**Noncommercial and Commercial Agents for Cell Tracking**

There are a variety of commercial and noncommercial fluorinated labelling agents currently available for use for cell labelling. These include linear PFCs such as the PFPE Cell Sense (CS-1000, CS-1000 ATM and fluorescently tagged CS-ATM DM Red, Green, NIR),\(^{32–38}\) V-Sense (VS-1000H),\(^{37,39,40}\) and cyclic PFCs such as PFCE-based agents,\(^{29,41–44}\) including VS-580H, which is a commercial PFCE.\(^{45–47}\) as well as other PFC formulations such as perfluorooctyl bromide (PFOB),\(^{31}\) perfluorodecalin (PFD),\(^{31}\) trans–bis-perfluorobutyl ethylene (F-44E),\(^{33}\) and superfluorinated compounds (eg, PERFECTA\(^{40}\) and \(^{39}\)FIT).\(^{49}\) These latter formulations aim to provide more SNR per cell (by fitting even more \(^{19}\)F atoms per molecule within the labels while maintaining small particle sizes) and adding additional functionality such as the ability to cleave the molecule apart for easy clearance by enzymatic action.\(^{48,50}\) Additional information on the hydrodynamic diameter and specific target of many PFC agents has been well summarized in previous reviews.\(^{51}\)

At the time of writing this article, Cell Sense and V-Sense are the two commercially available PFCs used for cell tracking in MRI, which are manufactured by Celsense Inc. They have developed several formulations of ex vivo and in situ cell labels, which were originally filed for patent on May 2, 2008 (no. PCT/US2009/002706). These include fluorinated emulsions (CS-1000, CS-580, VS-1000H, VS-580H) as well as other formulations that incorporate fluorochromes (CS and VS—ATM DM Red, Green, and NIR) for detection with MRI and fluorescence microscopy (ie, dual-labeled cells). Formulations using the numerical suffix “1000” are composed using PFPE, whereas those using “580” are composed from PFCE. To our knowledge, this company manufactures the only Food and Drug Administration-approved PFC label suitable for clinical cell tracking (ie, CS-1000) providing groundwork and a desirable research route for translational cell tracking and cellular therapy clinical trials. The safety of some PFCs in biomedical applications has been investigated previously. The PFC PFOB has been characterized and used as a blood substitute in large quantities.\(^{24,52}\) The amounts of PFC used as in situ and ex vivo agents for cell tracking are quite small in comparison with the quantities used as blood substitutes. This reduces the concern of residual
label and clearance over time. Clearance of PFC from the body is primarily achieved via the reticuloendothelial system and the lungs.52

**Cell Quantification from Imaging**

The ability to quantify the MRI signal obtained from 19F images of PFC-labeled cells is paramount to the development of future cellular therapies leading to conclusions about cell fate after administration. Ex vivo techniques allow for the quantification and potential to measure absolute cell counting from MR images. The processes involved are depicted in Figure 2 and are as follows. Cells are first labeled by incubating them with a 19F-based labelling agent (typically 48 hours). Three important measurements are required for quantification: The fractional PFC content per cell, denoted Fc, the SNR obtained from a uniform reference phantom (typically a dilution of the original cell labelling agent), and the SNR obtained from the regions of interest containing the cells themselves. Obtaining Fc is an extra step using a small fraction of the labeled cells separated from the transplant batch, as shown in process 1. To calculate Fc, this known quantity of cells is characterized using NMR and its spectrum is compared with a reference possessing a known concentration of 19F within the same NMR tube (trifluoroacetic acid [TFA]). Process 2 involves obtaining conventional 1H MR images in animal models or human beings after the injection of 19F-labeled cells to obtain the underlying anatomy at high resolution. Finally, in process 3, 19F MRI is performed depicting 19F signal from the reference phantom as well as the injected labeled cells. Obtaining the SNR values from injected cells and the reference phantom within these images, together with Fc, enable the estimation of the number of cells detected within an image. These methods are described in detail by Srinivas et al.51 Numerous in vitro quantification studies using this method have reported a Pearson correlation coefficient ($R^2$) of $>0.95$ between the observed number of cells and the true number of cells demonstrating accuracy and repeatability.51–55 Celsense Inc. has developed a postprocessing tool called Voxel Tracker34,53 for use with the company’s contrast agents, though this software may be suitable in principle for quantifying any cells labeled using 19F-containing agents (commercial or not). Other softwares commonly used for quantifying labeled cells include ImageJ and MATLAB, which offer more flexibility in postprocessing choices. Quantification of signal from in situ labeled cells also relies on the use of a uniform reference phantom, producing uniform signals within the image where, for example, inflammation correlates are to be quantified. Because the relationship between SNR and PFC content within each voxel is linear, it is easy to derive a correlation between the amount of SNR produced by labeled cells with that of known reference. From this,

![Cell labelling](image1.png) ![Labelled cell utilization](image2.png)

**Figure 2.** This figure depicts the ex vivo labelling process for absolute labeled cell quantification. During the cell-labelling phase, cells are first incubated with a 19F-based agent for up to 48 hours in order for 19F spins to become internalized within cells. Labeled cells are then utilized in three different processes. Process 1 demonstrates the performing of NMR on a small sample of these labeled cells to obtain their fractional fluorine content (Fc). Process 2 involves conventional 1H imaging of animals and human beings post injection to provide the underlying anatomy. Process 3 involves 19F imaging of animals and human beings to provide signals from both a reference phantom of known concentration and signals from the injected cells. The signals from these images, combined with Fc, allow for quantification of injected cells.
a reliable inflammation index can be generated by quantifying the SNR obtained from different organs within the region of interest. Unfortunately, estimation of the number of inflammatory cells is currently not possible due to the inability to measure FC for this mode of labelling.

Physical Properties, Hardware, Pulse Sequences, and Reconstruction
In addition to the various labelling agents available, raw numbers of 19F per molecule, relative chemical shifts, MRI hardware, and pulse sequence development play an important role in increasing the sensitivity and detectability of PFC-labeled cells.

Important physical properties of commonly used PFCs are their spin–lattice ($T_1$) and spin–spin ($T_2$) relaxation rates, chemical shift properties, and spectral strength (number of equivalent 19F atoms). Table 1 summarizes many of these properties for PFPE- and PFCE-based labelling agents. Identification of resonant frequencies of novel PFCs is achieved by comparing to reference samples containing known quantities of 19F atoms. Typical references include trichlorofluoromethane (TFE) and the more commonly reported reference, TFA. Different PFCs possess different chemical shift values, mono or multispectral features, and different relaxation times. PFPE and PFCE are separated by 1.9 ppm when measured independently, relative to CFCl3 (another reported reference chemical). PFPE has a spectrum characterized by two distinct peaks separated by 0.2 ppm. The primary peak is ten times stronger than the secondary peak and has a chemical shift of −15.58 ppm relative to TFA. The second peak is generally not observed in vivo due to its signal strength being an order of magnitude smaller than the main peak and its shorter relaxation time. The $T_1$ of the primary peak is 2.2 times shorter than that of PFCE with a value of 437 ms at 11.7 T.19,37,58,61 Boehm-Sturm et al reported $T_1/T_2$ of both free and cell-internalized PFPE of 280/153 ms and 380/68 ms, respectively, also at 11.7 T.31 Ahrens et al reports $T_1/T_2$ values of 470/250 ms for PFPE at the clinically relevant field strength 3 T.57 In contrast to PFPE, PFCE has the benefit of exhibiting a single strong peak owing to its circular symmetry. Longitudinal relaxation times are longer for PFCE, which is why some users prefer PFPE. Intracellular $T_1$ of a particular PFC has been reported to be 800 ms at 11.7 T.58 Ruiz-Cabello et al investigated cationic PFCE at 9.4 T and reported $T_1/T_2$ values of 580 ms/536 ms, and Jacoby et al reported $T_1/T_2$ values of 600 ms/300 ms using a different emulsion formulation of PFCE. They include a table of relaxation times for the complicated spectra of PFOB, PFCE, PFBD, and F44E. A thorough investigation of the relaxation of PFPE and PFCE in neat and emulsion forms was conducted recently by Kadayakkara et al investigating neat and emulsified samples at different field strengths (7–14.1 T) and for a range of different temperatures (256K–323K). Important reported trends include that for PFCE, $R_2$ ($R_1 = 1/T_1$) decreased as a function of temperature for each of the three different field strengths and $R_1$ increased as a function of field strength. Emulsions exhibited a reduction in $R_1$ by 20% compared with neat samples. PFPE exhibited an increase in $R_1$ as a function of field strength and as a function of temperature but reached a maximum $R_1$ value at a specific temperature that was different for each field strength. Knowledge of these trends will help improve the development of customized PFC cell-tracking probes at clinical field strengths and for eventual clinical translation.

Research utilizing PFCs for cell tracking requires additional hardware not available on all scanners. Broadband amplifiers capable of nonproton excitation are generally required as are dedicated radiofrequency (RF) coils capable of detecting the 19F resonance. The separation between 1H and 19F frequencies is small compared with that of other nuclei (−4–30 kHz between 1.5 and 11.7 T). For clinical field strengths, existing amplifiers may be sufficient for the detection of 19F signals without the need for an expensive multinuclear package. RF coils capable of detecting both 1H and 19F signals are desirable for both preclinical and clinical imaging. Some examples include single-tuned linear coils and dual-tuned coils that can be manually or electronically switched between scans. A big advantage of dual-tuned coils is that switching between 1H and 19F modes can be performed without having to remove the sample, animal, or patient from the bore. Together with these specialized RF coils, MRI pulse sequences are needed. The majority of reported work using PFCs for MRI cell tracking utilized fast spin–echo pulse sequences such as rapid acquisition with relaxation enhancement,27–29,32,33,40,42,43,45,46,59,60 and UTE imaging.52 These sequences are capable of improving SNR by either averaging hundreds of times or minimizing signal dephasing. Another advantage comes from the short echo times (TEs) utilized by both of these sequences, which result in spin-density weighted images allowing for quantification. The improvement in imaging speed comes at a cost requiring higher gradient performance. A multipulse echo sequence has also been developed suitable for possible future cell-tracking applications using PFCE. It is interesting to note that the initial investigation into imaging 19F agents utilized steady-state free precession techniques as early as 1977.2

Image reconstruction considerations are important as well. Detecting small populations of PFC-labeled cells does not yield exceedingly high SNR values (~5–15), and SNR thresholds (to distinguish real signal from background) are typically quite low (between 2.5 and 5). Postprocessing is required for low SNR data by performing Rician noise corrections and for removing artifacts caused by chemical
shifts.\textsuperscript{65} Compressed sensing is an imaging method that uses sophisticated image reconstruction to form images from sparsely filled $k$-space data, with the advantage of significant shortening of scan time.\textsuperscript{66–68} Patient motion can further impact image quality and reduce SNR, which has implications on absolute cell quantification.\textsuperscript{69}

Applications of PFC to Cell Tracking
Since 2005, PFC cell tracking has been applied to numerous cell types and disease models, including the tracking of endothelial cells,\textsuperscript{33} inflammation (macrophages),\textsuperscript{26–29,31,42,45,47,59,70–73} monocytes,\textsuperscript{30,39,74} cancer cells,\textsuperscript{75–78} human-derived mesenchymal stem cells (hMSCs),\textsuperscript{36,37,61} stem/progenitor cells,\textsuperscript{58} DCs,\textsuperscript{4,25,34,41,44,79,80} T-cells,\textsuperscript{38,53,78,81} hematopoietic stem cells,\textsuperscript{35} neural stem cells,\textsuperscript{32,33,43} and natural killer cells.\textsuperscript{82}

Mesenchymal stem cells (MSCs) are of recent interest in cellular therapy due to their ability to modulate various immune responses\textsuperscript{83} and their capability of differentiating into various tissues such as bone, cartilage, and adipose.\textsuperscript{84} Not surprisingly, PFC cell tracking has been recently used to investigate mouse-derived MSC (mMSC) and hMSC.\textsuperscript{36,37,61} The development of hardware and imaging protocols in these animal models is essential to lay the groundwork for future clinical translation.\textsuperscript{36,37,61} A recent study investigated the fate of MSC implants labeled using CS-1000 in two mouse transplant models using immunocompetent and immunocompromised mice.\textsuperscript{61} mMSC (2 × 10$^6$) and hMSC (1.5 × 10$^6$) were delivered to competent and compromised mice, respectively, and were imaged at four time points for up to 17 days. For both mice, day zero quantification agreed well with the expected implanted cell numbers. Over time, $^{19}$F signal decreased, and in the immunocompromised mice, it decreased at a slower rate than those with immunocompetent systems. Results were consistent with the performed immunohistochemistry. Here, imaging with $^{19}$F-MRI provided an advantage over traditional postmortem tissue analysis by providing longitudinal cell information from the same animal. Another point of impact of this work is the fact that this is the first detailed report of the problem of the use of isoflurane as an anesthetic for preclinical cell tracking using PFCs.

Isoflurane and $^{19}$F Cell Tracking
Isoflurane is a fluorinated anesthetic commonly used in experiments involving animal models and has the potential to corrupt signals originating from PFC-labeled cells due to buildup within fat/adipose tissue and potentially from within the lung. Isoflurane has two resonances that are very close to the resonances of PFCs commonly used in cell tracking (PFPE and PFCE) with values of −6.8 and −13.9 ppm relative to TFA (eg, PFPE is at −16 ppm relative to TFA).\textsuperscript{85} A table of isoflurane chemical shifts relative to TFA in common solvents can be found here.\textsuperscript{86} Relaxation times of these peaks depend on field strength and their local environments. $T_2^*$ is < 5 ms in brain tissue\textsuperscript{87} and longer in adipose tissue/fat where isoflurane can be deposited.\textsuperscript{87,88}

The problem of isoflurane detection in animal models of PFC cell tracking is not widely discussed in the literature and where it is, mere avoidance of the $^{19}$F signals from isoflurane is mentioned by using alternate anesthetics. Furthermore, image acquisition parameters helpful for pulse-sequence design to avoid exciting isoflurane are seldom given (eg, RF pulse shape and duration). Boehm-Sturm et al described the use of ketamine/xylazine maintained by syringe pump for their animal experiments to avoid the $^{19}$F signals due to isoflurane.\textsuperscript{33} van Heeswijk et al also acknowledged isoflurane as a potential problem and presented spectra showing peaks due to isoflurane in close proximity to PFCs, albeit at a signal strength an order of magnitude lower than those of the PFCs.\textsuperscript{89} Ribot et al recently utilized pentobarbital rather than isoflurane to avoid isoflurane signal.\textsuperscript{89} The first reported use of isoflurane in experiments involving cell-tracking applications was in 2010 in rats\textsuperscript{76} and mice.\textsuperscript{34} Before that, ketamine/xylazine was the preferred method of anesthesia presumably to avoid detection of isoflurane. Today, isoflurane is used extensively, even in cell-tracking applications, likely attributed to its ease of use in implementation.\textsuperscript{25,27,30,39,40,46} With these reports and physical attributes in mind, it would seem that isoflurane is still very difficult to detect and may not be worth worrying about. However, working toward clinical translation, animal models will have to move to lower field strengths (≤3 T, reducing spectral separation in Hertz). This may require increases in scan time resulting in an increase in isoflurane deposition in fat due to reduced PFC SNR. More efficient imaging techniques will also increase sensitivity to low-density $^{19}$F sources due to efficient use of SNR/t and shorter TE (eg, TE 1.8 ms\textsuperscript{40}), which is simultaneously beneficial for detecting signals from both cells and isoflurane. Under these conditions, attention to isoflurane may be required using solutions such as shaped RF pulses employed to exclude excitation of unwanted peaks\textsuperscript{62} or reversion to nonfluorinated anesthetics for animals. Figure 3 demonstrates the improvement (reduction of isoflurane signal) in $^{19}$F images when considering excitation pulse parameters such as shape and pulse duration.

Clinical Cell Tracking
The first use of PFC-labeled cell tracking in human beings was recently demonstrated by Ahrens et al, who described the results of a phase I clinical trial in the United States using a DC vaccine designed for stage 4 colorectal cancer treatment.\textsuperscript{57} Since the strength of treatment is proportional to the number of migrating DC, it is essential that researchers have a noninvasive, quantitative technique to monitor therapy. In addition, since lymph node removal is not practical in the clinical setting, imaging provides the only available information for dose optimization. Five patients were enrolled and assigned into groups of low dose ($N = 2$ at $1 \times 10^6$ cells) and high dose ($N = 3$ at $1 \times 10^7$ cells) labeled DC vaccines using clinical-grade PFC agent CS-1000. DCs were imaged using a FLASH sequence coregistered with $^1$H images at 4 and 24 hours post transplant. Images obtained from this study are shown in Figure 4. Only the high-dose
groups revealed detectable and countable cells. The cell counts at 4 hours were equivalent to the delivered dose and approximately half of that at 24 hours consistent with cell efflux from the initial injection site as cells migrate elsewhere. However, the signal was only detected at the injection site and not at the intended target organ: the draining lymph nodes. The significance of this work is that PFC-labeled cells using Food and Drug Administration-approved agents have been safely applied to human beings and were detected using MRI at 3 T as an important proof-of-principle experiment utilizing a DC vaccine.

### Lung Imaging Using Inert Fluorinated Gas MRI

$^{19}$F-based MRI has a role not just in imaging microbiological environments (cell tracking) but also within macrobiological environments, such as the lungs’ airspaces. Lung MRI using inert fluorinated gases as contrast agents is another field enjoying recent success due to technological advancements for $^{19}$F detection. Hyperpolarized (HP) noble gas MRI of the lung is a field that is >20 years old, born out of the desire to study the effect of anesthesia on brain function. The first HP gas lung image was obtained using MRI and HP $^{129}$Xe in excised mouse lungs. Since then, this field has flourished initially due to the success and ease of use of HP $^3$He lung imaging. Together, these nuclei have been used to investigate and address various chronic respiratory diseases and acute lung injuries in both clinical studies and animal models, forming the basis of HP noble gas lung imaging. These gases have the ability to provide anatomical and functional information from within the lungs of human beings and rodents such as static ventilation imaging, characterization of apparent diffusion coefficients (ADCs), and gas exchange, including those from models of emphysema, asthma, fibrosis, radiation-induced lung injury, and inflammation due to fungal spores.

HP gas MRI of the lung requires the use of expensive polarizers to achieve high SNR within the lung. In hyperpolarizing these isotopes, they receive enhancement of their nuclear polarization by a factor of $1 \times 10^5$ compared to their thermal equilibrium values resulting in their high SNR and excellent image quality. Furthermore, the isotopes used are also expensive and, in some cases, are becoming increasingly scarce (e.g., $^3$He). $^3$He has been used quite extensively over the years; however, within the past decade, interest has shifted toward $^{129}$Xe due to improved polarization techniques for $^{129}$Xe, case in obtaining these isotopes, and ability to perform novel functional measurements such as gas exchange at the blood gas barrier, perfusion measurements, and brain function due to $^{129}$Xe’s high solubility in tissues and blood compared with $^3$He. $^{129}$Xe has a natural abundance of 26% and small gyromagnetic ratio (~28% of $^3$H). Though xenon is a valuable by-product of the liquid air industry and is quite easy to obtain, mixtures enriching the $^{129}$Xe isotope can greatly increase SNR but at a much higher monetary cost.

Fluorinated gases require no such polarizer, are less costly to purchase, and the signal is derived from its thermal equilibrium polarization, just like conventional $^3$H MRI. In addition, these gases comprise molecules possessing multiple NMR equivalent fluorine atoms collectively enhancing their detectability. The most common fluorinated gases used to date for lung imaging (especially in human beings) are SF$_6$ and C$_2$F$_6$. C$_3$F$_8$ has also been studied extensively in animal models.

---

**Figure 3.** (A) Strong isoflurane signal (red arrow) is detectable following accumulation in the fat pads of mice after excitation with the standard Gaussian filtered sinc pulse (B). This signal is chemically shifted from the fat pad (blue arrow), compared to that of the reference tube above. (C) The mouse was then scanned with a non-filtered sinc pulse (D). Fourier transform of this pulse produces a narrower excitation that did not excite isoflurane $^{19}$F atoms, reducing unwanted background signal from isoflurane. Both images have been windowed to the same level, and brightened to show the noise distribution. (B) The filtered pulse shape in time space is shown, with a width of 0.66 ms. (D) The non-filtered sinc pulse width is much broader with a FWHM of 1.32 ms in time space. Image courtesy of Gaudet et al$^{13}$ and reproduced with permission.
The use of tetrafluoromethane (CF$_4$) has also been reported. These are not rare gases unlike $^3$He and $^{129}$Xe. Furthermore, use of these gases for MRI enables safe and repeatable imaging that is noninvasive, nonionizing and there is no $^{19}$F background.

The first $^{19}$F gas lung images were obtained in 1982 by Heidelberger and Lauterbur using CF$_4$ in excised rabbit lungs, preceding the first HP gas lung images by 12 years. Shortly after, images were obtained in excised healthy canine lungs. After a long gap in $^{19}$F MRI lung reports, Kuethe et al demonstrated continuous breathing of C$_2$F$_6$ in rats, and it was not until 10 years later that the first human lung images were reported by Wolf et al using a mixture of SF$_6$ and oxygen. Though these gases currently produce images that are lower in quality compared with HP gas images, they come with many benefits, as described below. These gases are important because they provide similar diagnostic information and biomarkers as HP gases (eg, static ventilation images, ADC, and surface-to-volume ratio) and complement them as alternative methods to probe healthy and diseased lungs.

Inert fluorinated gases are not the only methods available to perform MRI of the lung without the use of HP gases. For completeness, oxygen-enhanced methods, Fourier decomposition, and $^1$H UTE exist. Recent comprehensive reviews of lung imaging using MRI have been presented.

**Physical Properties, Hardware, Pulse Sequences, and Reconstruction**

Of the commonly used fluorinated gases (ie, SF$_6$ and C$_3$F$_8$), there are several key physical properties that impact their effectiveness in the MRI of the lung. These include their relaxation times, spectral features, number of equivalent $^{19}$F atoms, and diffusion properties. Table 1 summarizes the key properties for these gases and C$_2$F$_6$.

![Figure 4. Result of the processes described in Figure 2 as applied to human cell tracking. In vivo MRI in patients following intradermal DC administration into quadriceps. In these patients, $1 \times 10^7$ labeled cells were injected. (A) A representative $^{19}$F Magnetic Resonance Spectroscopy (MRS) spectrum of the patient at four hours postinoculation. The DCs appear as a single narrow peak. “Reference” is from an external tube containing TFA placed alongside the patient. (B) Axial composite $^{19}$F/$^1$H images of the right thigh at 4 hours postinoculation in three patients, a 53-year-old female (left), a 45-year-old female (middle), and a 61-year-old male (right), where DCs are rendered in hot-iron pseudo color and the $^1$H anatomy is displayed in rescale (F, femur; RF, rectus femoris; SFA, superficial femoral artery; LN, inguinal lymph node). (C) The results of the in vivo quantification of apparent cell numbers using the $^{19}$F MRI data, measured in two patients. By 24 hours postinoculation, roughly half of the injected DCs were still present at the injection site. Image courtesy of Ahrens et al and reproduced with permission.](image-url)
relaxation times of these peaks separately and the relaxation values reported are taken to be that of the main peak.

Unlike PFCs used for cell tracking, the diffusion coefficient of these $^{19}$F gases plays an important role for probing lung microstructure and performing functional lung imaging. The theory and use of $^{19}$F gases for diffusion-weighted MROI is extensively described in these reports.$^{112,113,115–117}$

Fluorinated gases have a good record of safety due to their inertness, supported by their use in recent human imaging studies as inhaled contrast agents and lack of reported adverse events in the literature. Furthermore, these gases can be directly mixed with physiological concentrations of oxygen (21%) without large penalties in SNR, unlike HP gas agents.$^{113}$ The ability to create normoxic mixtures eliminates the risks involved with long-duration breath-holds of anoxic gas volumes and enables repeated breathing and even washout maneuvers in order to reach a steady state of $^{19}$F gas within the lung as well as perform dynamic lung imaging.

The hardware challenges for $^{19}$F lung imaging are similar to those for $^{19}$F cell tracking. Amplifiers capable of excitation for a range of $^{19}$F resonances (~150 ppm for $^{19}$F gases$^{114}$) are required as are dedicated RF coils capable of detecting the $^{19}$F resonance. Lung imaging is commonly performed at clinical field strengths between 1.5 and 3 T. Imaging may prove difficult at higher field strengths due to the high magnetic susceptibility of lung tissue at the air–tissue interfaces. In fact, the theoretically predicted optimum field strength for HP gas human lung MRI is between 0.1 and 0.6 T.$^{125}$ Specific absorption rate (SAR) depends on the field strength and may require additional safety restrictions at field strengths $>3$ T. RF coils capable of detecting both $^1$H and $^{19}$F signals are desirable for both preclinical and clinical imaging, though designs exist that allow the use of the scanners’ native body coil for $^1$H by actively detuning the $^{19}$F coil without removal of the coil or patient.$^{109,110,126}$ Furthermore, the spatial extent of $^{19}$F signals is quite larger in comparison with cell-tracking applications (eg, 5 L lung volume vs. 1 mL injection sites) requiring different RF coil solutions such as large volume coils of birdcage design or flexible surface coils. Unlike cell tracking, which for some applications requires minimal penetration depth (~1–2 cm), lung imaging requires uniform excitation of the entire lung, requiring high transmit uniformity and power. Birdcage designs have been employed for $^3$He$^{91,127}$ $^{129}$Xe$^{128}$ and $^{23}$Na$^{28}$ but to our knowledge, no $^{19}$F coils of this design have been reported. The use of a coil of this type for $^{19}$F lung imaging would provide high $B_0$ uniformity and require less effort in setup from patient to patient. Other reported coils used for $^{19}$F lung imaging employ flexible volume coils with a detuning circuit to allow for $^1$H body coil imaging.$^{109,130}$

This design allows for easy imaging between $^1$H and $^{19}$F frequencies and also provides patient comfort. Due to the flexibility of the coil, however, $B_0$ mapping is required on a case basis in order to correct the images for inhomogeneous $B_0$ between patients.

Due to the short relaxation times of these gases, MR pulse sequences having short repetition time (TR) and TE are desirable. The shorter TR reduces the overall scan time providing a time-saving that can then be used to enhance SNR by rapid signal averaging (subject to specific absorption rate limitations). Several sequences used for imaging $^{19}$F gases have been described in the literature, including 3D gradient recalled echo (GRE),$^{10,110,131}$ 2D/3D FLASH,$^{6,132}$ UTE,$^{109}$ COMSPIRA,$^{94,136,117}$ and X-centric, a type of GRE.$^{124}$ UTE and 3D GRE methods have been compared demonstrating improvements in SNR for UTE at the cost of edge resolution.$^{131}$ X-centric has also been compared to UTE and GRE methods in a resolution phantom demonstrating both improvements in SNR and sustained resolution compared with UTE and GRE at the cost of a second scan (because only 50.5% of $k$-space is collected per readout gradient polarity). COMSPIRA is a hybrid sequence merging projection reconstruction and spiral readouts. It is insensitive to motion due to the use of oversampling of the low spatial frequencies in $k$-space and has been used to measure ADC maps in rats.

**Isoflurane and $^{19}$F Lung Imaging**

Though isoflurane is in common use as an anesthetic for animal models used in cell tracking, there is no description of isoflurane posing a problem for $^{19}$F lung imaging. This is likely due to the fact that the described preclinical research in rats and pigs all used injectable anesthetics such as sodium pentobarbital, ketamine, xylazine, and thiopental rather than inhaled anesthetics such as isoflurane and halothane to deliberately avoid $^{19}$F signals from their anesthetics.

**Static Lung Imaging**

Static ventilation lung imaging is the easiest and most common method of lung imaging to perform. In general, a volume of inert fluorinated gas is introduced to the lungs using a ventilator (for animals) or inhaled from a plastic bag (for human beings) as depicted in Figure 5. In either case, once the dose is delivered, the animal/human being engages in a breath-hold and MRI is performed during a modest breath-hold length of up to 15 seconds. During the breath-hold, motion artifacts or blurring due to breathing are of no concern due to the temporarily suspended respiratory motion. The gas is then exhaled and the experiment can be repeated. In some cases, the volume of the lung is washed out using prebreaths of $^{19}$F gas before the imaging breath-hold is initiated in order to provide a uniform distribution of inert fluorinated gas to all possible air spaces. There may be inherent differences in lung volume between $^{19}$F images and $^1$H due to the fact that separate breath-holds are needed for each. These differences are controlled to the best of the researcher’s ability (eg, functional residual capacity (FRC) + 1 L of $^{19}$F gas or air). The first $^{19}$F gas lung images obtained by Heidelberger and Lauterbur in 1982$^{205}$ as well as those demonstrated by Rinck$^{106,107}$ and Keuthe,$^{198}$ are the first examples of static lung imaging.
Dynamic Lung Imaging

Dynamic lung imaging using fluorinated gases was first described by Schreiber et al using SF$_6$ in pig lungs to measure wash-in and washout kinetics using dynamic gradient echo imaging. Kuethe et al measured the volume of rat lungs during the respiratory cycle of mechanically ventilated rats using SF$_6$ in a disease model of elastase-induced emphysema. By calibrating NMR signal strength to known volumes of SF$_6$ within the laboratory, fast spectroscopic techniques can be used to measure in vivo lung volume with high temporal resolution (20 measurements per second). Wolf et al investigated MRI of dynamic wash-in of fluorinated gas using C$_2$F$_6$ in pig lungs to optimize image acquisition for very short acquisition times with respectable image quality in as short as two seconds. They also investigated C$_3$F$_8$ in a lung washout study and, for the first time, demonstrated and quantified washout dynamics under high-frequency oscillatory ventilation. Scholz et al compared $^{19}$F gas-derived measurements of lung function and did a direct comparison with nonimaging respiratory gas analysis measuring alveolar gas fraction in pigs. Ouriadov et al investigated and compared ventilation mapping using SF$_6$ and PFP after establishing improved resolution and SNR using the X-centric pulse sequence compared with UTE and fast gradient recalled echo (FGRE) within a resolution phantom. X-centric can achieve relatively short TE (~0.5 ms) while maintaining the benefits of Cartesian style acquisition.

Functional Lung Imaging (Diffusion, paO2, Fractional Ventilation, and Gradients)

Expanding on the possible detectable biomarkers using fluorinated gases for lung MRI, ADCs of gases, oxygen partial pressure (paO2), ventilation perfusion ($V/Q$) measurements, and fractional ventilation parameter ($r$) and $r$ gradients have been reported. The first application of diffusion weighted imaging using $^{19}$F in excised human lungs was reported by Jacob et al. C$_2$F$_6$ was used to distinguish between healthy and emphysematous excised human lungs and described the benefits of C$_2$F$_6$ over SF$_6$, CF$_4$, and C$_3$F$_8$ for ADC measurements due to its favorable relaxation times, monochromatic spectrum, and diffusion coefficient. Pérez-Sánchez et al demonstrated the first in vivo ADC maps in an animal model using rats breathing SF$_6$ at 4.7 T. They reported adequate SNR for the formation of ADC maps as well as a protocol to keep imaging time short. Kuethe et al demonstrated the use and sensitivity of SF$_6$ in a rat model of obstructed lungs to measure oxygen partial pressure. Regions of poor $V/Q$ ratio appeared brighter within images due to their shortened $T_1$ due to the higher concentrations of oxygen (poor gas exchange). Ouriadov et al were the first to use and compare SF$_6$ and C$_3$F$_8$ to generate $r$ maps and calculate the gravitational dependence of $r$ in rat lungs. They demonstrated that the use of either gas was suitable for these functional measurements within rats with sufficient SNR and may be translatable to clinical scale imaging.
Clinical Lung Imaging

The first human lung images obtained using $^{19}$F gas were reported by Wolf et al.\(^6\) using a mixture of SF\(_6\) and oxygen. Recent static ventilation imaging in human beings has been reported using enhanced techniques to overcome the low sensitivity of $^{19}$F gas lung imaging. The use of a large pre-washout of the lungs by inhaling several breaths of fluorinated gas mixed with 21% oxygen from bags\(^{130}\) or delivery system (Physiorack)\(^{126}\) greatly increases the number of $^{19}$F spins within the lungs prior to imaging. Couch et al utilized a large 5 L bag of gas (C\(_2\)F\(_6\) or SF\(_6\) mixed with 21% of oxygen) to washout lungs prior to inhalation of 1 L of gas from a second bag to ensure imaging was carried out at FRC + 1 L.\(^{109}\) They employed an UTE imaging sequence (3D UTE) and compared the results with the previously reported FGRE images reporting a factor of 2 enhancement in SNR. Representative UTE images are shown in Figure 6.

Halaweish et al performed the first $^{19}$F enhanced dynamic imaging studies on healthy volunteers and volunteers with emphysema and chronic obstructive pulmonary disease, demonstrating differences in ventilation heterogeneity and gas trapping in those with chronic obstructive pulmonary disease.\(^{113}\) Due to the short relaxation times of these fluorinated gases, sequences employing shorter TEs can greatly impact SNR in a beneficial way. Finally, measurement of surface-to-volume ratios\(^{114}\) and gravitational gradients\(^{114}\) have also been demonstrated in human lungs using FPF; however, a full study comparing healthy lungs with diseased lungs remains to be reported.

Conclusions

The use of fluorinated contrast agents for MRI of cell tracking, lung imaging, and drug development represents a large body of scientific research. Various problems and solutions, owing to the range of field strengths (1.5–11.7 T) that this research spans across, the relaxation properties of different fluorinated contrast agents, and practical issues have been described. UTE strategies, isoflurane usage, and detection of $^{19}$F agents at clinical field strengths are where cell tracking and lung imaging may mutually benefit each other. Cell tracking may benefit from the development of UTE strategies for lung imaging, which may improve detection of $^{19}$F-labeled cells in the presence of iron for multiecell population labeling (eg, Hitchens et al\(^{19}\)). Preclinical $^{19}$F lung imaging does not utilize isoflurane at all. Alternate anesthesia strategies would eliminate the problems that isoflurane may cause for cell tracking. With clinical translation in mind, cell tracking may greatly benefit from technological advances in lung imaging since the majority of research in that field is performed at 1.5 and 3 T. Novel RF coils and arrays have been developed as well as pulse sequences designed to detect low concentrations of $^{19}$F. Fluorinated contrast agents are indeed versatile contrast agents well suited for probing the micro- to macrobiological environments, and future work will only enhance their utility in these important fields.

Acknowledgment

The authors thank Chelsey Foster for authoring figures 2 and 5.

Author Contributions

Wrote the first draft of the manuscript: MSF. Contributed to the writing of the manuscript: MSF, JMG, PJF. Agree with manuscript results and conclusions: MSF, JMG, PJF. Jointly developed the structure and arguments for the paper: MSF, JMG, PJF. Made critical revisions and approved final version: MSF, JMG, PJF. All authors reviewed and approved of the final manuscript.

REFERENCES

1. Goertj CJ, Broer LJF. Negative result of an attempt to observe nuclear magnetic resonance in solids. Physica. 1942;6(6):591–596.
2. Holland GN, Bottomley A, Hinshaw WS. $^{19}$F magnetic resonance imaging. J Magn Reson. 1977;28(1):133–136.
3. Tran HT, Guo Q, Schumacher DJ, Buxton RB, Matthey RF. $^{19}$F chemical shift imaging technique to measure intracellular pO2 in vivo using perfluorobenzene. Acad Radiol. 1995;2(9):756–761.
4. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005;23(8):983–987.
5. Briis G, Bollmann ME, Haberkorn U, Grellich L, Bachert P, Lorenz WJ. Mapping the biodistribution and catabolism of $^{19}$F-fluorostilbazole in tumour-bearing rats by chemical-shift selective $^{19}$F MR imaging. Magn Reson Med. 1995;34(3):302–307.
6. Wolf U, Scholz A, Terekhow M, et al. Fluorine-$^{19}$MRI of the lung: first human experiment. International Society for Magnetic Resonance Imaging Proceedings. Toronto, Ontario, Canada. 2008.
7. Bartunik D, Aebisher D. $^{19}$F applications in drug development and imaging—a review. Biomed Pharmacother. 2014;68(6):813–817.
8. Ntzikriostis V. Fluorescence molecular imaging. Annu Rev Biomed Eng. 2006;8:1–33.
9. Phelps ME. Molecular imaging with positron emission tomography. Annu Rev Nucl Part Sci. 2002;52(1):303–338.
10. Stoddila KZ, Blackwood KJ, Kong H, Prato FS. A method for quantitative cell tracking using SPECT for the evaluation of myocardial stem cell therapy. Nucl Med Commun. 2006;27(10):807–813.
11. Stoddila KZ, Blackwood KJ, Prato FS. Tracking transplanted cells using dual-radionuclide SPECT. Phys Med Biol. 2006;51(10):2619–2632.
12. Bulte JW, Hoekstra Y, Kamman RL, et al. Specific MR imaging of human lymphocytes by monoclonal antibody-guided dextran-magnetic particles. Magn Reson Med. 1992;25(1):148–157.

13. Bulte JW, Ma LD, Maglin RL, et al. Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome-mediated incorporation of dextran-magnetic particles. Magn Reson Med. 1993;29(1):32–37.

14. Yeh TC, Zhang W, Ildstad ST, Ho C. Intracellular labeling of T-cells with superparamagnetic contrast agents. Magn Reson Med. 1993;30(5):617–625.

15. Strobel K, Hoer F, Schmid F, Wachsmuth L, Löffler F, Faber C. Early detection of lung inflammation: exploiting T1 effects of iron oxide particles using UTE-MRI. Magn Reson Med. 2012;68(6):1924–1931.

16. Zhou R, Idiyrullin D, Moeller S, et al. SWIFT detection of SPION-labeled stem cells grafted in the myocardium. Magn Reson Med. 2010;63(5):1154–1161.

17. Heyns C, Ronald JA, Mackenzie LT, et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med. 2006;55(1):23–29.

18. Shapiro EM, Medford-Davis LN, Fahmy TM, Dunbar CE, Koretsky AP. Antibody-mediated cell labeling of peripheral T-cells with micron-sized iron oxide particles (MPIOs) allows single cell detection by MRI. Contrast Media Mol Imaging. 2007;2(3):147–153.

19. Ribot EJ, Foster PJ. In vivo MRI discrimination between live and lysed iron-labelled cells using balanced steady state free precession. Eur Radiol. 2012;22(9):2027–2034.

20. Ahrens ET, Young WB, Xu H, Pusateri LK. Rapid quantification of inflammation in vivo using the bSSFP sequence. Magn Reson Med. 2010;63(7):163–170.

21. Yu JX, Hallac RR, Chiguru S, Mason RP. New frontiers and developing applications in (19)F MRNMR. Prog Nucl Magn Reson Spectrom. 2013;70:25–49.

22. Bulte JW. Hot spot MRI emerges from the background. Nat Biotechnol. 2005;23(8):945–947.

23. Waiczies H, Lepore S, Chirouze M, et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One. 2011;6(7):e21989.

24. Bulte JW, Young WB, Xu H, Pusateri LK. Rapid quantification of inflammation in vivo using magnetic resonance imaging. Nat Immunol. 2013;14(10):755–763.

25. Delakban A, Hamilton AM, Fink CA, et al. Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(5):469–483.

26. Sinivas M, Heerschap A, Ahrens ET, Fidler CG, de Vries JJ. (19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol. 2010;28(7):363–370.

27. Strobel K, Hoer F, Schmid F, Wachsmuth L, Löffler F, Faber C. Early detection of lung inflammation: exploiting T1 effects of iron oxide particles using UTE-MRI. Magn Reson Med. 2012;68(6):1924–1931.

28. Boehr-Sturm P, Mengler L, Wecker S, Hoehn M, Kallur T. In vivo tracking of fluorine-labeled human MSC using the bSSFP sequence. Magn Reson Med. 2011;65(4):1144–1153.

29. Ahrens ET, Young WB, Xu H, Pusateri LK. Rapid quantification of inflammation in vivo using the bSSFP sequence. Magn Reson Med. 2010;63(7):163–170.

30. Heerschap A, Ahrens ET, Ho C. Tracking for Cancer Immunotherapy. Magn Reson Med. 2015;74(2):18–22.

31. Strobel K, Hoer F, Schmid F, Wachsmuth L, Löffler F, Faber C. Early detection of lung inflammation: exploiting T1 effects of iron oxide particles using UTE-MRI. Magn Reson Med. 2012;68(6):1924–1931.

32. WAiczies H, Lepore S, Chirouze M, et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One. 2011;6(7):e21989.

33. Ahrens ET, Young WB, Xu H, Pusateri LK. Rapid quantification of inflammation in vivo using magnetic resonance imaging. Nat Immunol. 2013;14(10):755–763.

34. Delakban A, Hamilton AM, Fink CA, et al. Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(5):469–483.

35. Sinivas M, Heerschap A, Ahrens ET, Fidler CG, de Vries JJ. (19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol. 2010;28(7):363–370.

36. Yu JX, Hallac RR, Chiguru S, Mason RP. New frontiers and developing applications in (19)F MRNMR. Prog Nucl Magn Reson Spectrom. 2013;70:25–49.

37. Bulte JW. Hot spot MRI emerges from the background. Nat Biotechnol. 2005;23(8):945–947.

38. Waiczies H, Lepore S, Janitzen N, et al. Perfluorocarbon particle size influences magnetic resonance signal and immunological properties of dendritic cells. PLoS One. 2011;6(7):e21989.

39. Ahrens ET, Young WB, Xu H, Pusateri LK. Rapid quantification of inflammation in vivo using magnetic resonance imaging. Nat Immunol. 2013;14(10):755–763.

40. Delakban A, Hamilton AM, Fink CA, et al. Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5(5):469–483.
125. Parra-Robles J, Cross AR, Santyr GE. Theoretical signal-to-noise ratio and spatial resolution dependence on the magnetic field strength for hyperpolarized noble gas magnetic resonance imaging of human lungs. *Med Phys.* 2005;32(1):221–229.

126. Halaweish AF, Charles HC. Physiorack: an integrated MRI safe/conditional, gas delivery, respiratory gating, and subject monitoring solution for structural and functional assessments of pulmonary function. *J Magn Reson Imaging.* 2014;39(3):735–741.

127. De Zanche N, Chhina N, Teh K, Randell C, Pruessmann KP, Wild JM. Asymmetric quadrature split birdcage coil for hyperpolarized 3He lung MRI at 1.5T. *Magn Reson Med.* 2008;60(2):431–438.

128. Ouriadov A, Farag A, Kirby M, McCormack DG, Parraga G, Santyr GE. Pulmonary hyperpolarized (129)Xe morphometry for mapping xenon gas concentrations and alveolar oxygen partial pressure: proof-of-concept demonstration in healthy and COPD subjects. *Magn Reson Med.* 2015;74(6):1726–1732.

129. Farag A, Peterson JC, Szekeres T, et al. Unshielded asymmetric transmit-only and endorectal receive-only radiofrequency coil for (23)Na MRI of the prostate at 3 tesla. *J Magn Reson Imaging.* 2015;42(2):436–445.

130. Halaweish AF, Moon RE, Foster WM, et al. Perfluoropropane gas as a magnetic resonance lung imaging contrast agent in humans. *Chest.* 2013;144(4):1300–1310.

131. Couch MJ, Ball IK, Li T, et al. Optimized Strategies for 19F MRI of Human Lungs and Comparison of UTE and Gradient Echo Imaging. *Proc Intl Soc Mag Reson Med.* 2014:22.

132. Wolf U, Scholz A, Heussel CP, Markstaller K, Schreiber WG. Subsecond fluorine-19 MRI of the lung. *Magn Reson Med.* 2006;55(4):948–951.

133. Schreiber WG, Eberle B, Laukemper-Ostendorf S, et al. Dynamic (19)F-MRI of pulmonary ventilation using sulfur hexafluoride (SF(6)) gas. *Magn Reson Med.* 2001;45(4):605–613.

134. Kuethe DO, Behl VC, Begay S. Volume of rat lungs measured throughout the respiratory cycle using 19F NMR of the inert gas SF6. *Magn Reson Med.* 2002;48(3):547–549.

135. Conradi MS, Saam BT, Yablonskiy DA, Woods JC. Hyperpolarized 3He and perfluorocarbon gas diffusion MRI of lungs. *Prog Nucl Magn Reson Spectrosc.* 2006;48(1):63–83.

136. Adolph NL, Kuethe DO. Quantitative mapping of ventilation-perfusion ratios in lungs by 19F MR imaging of T1 of inert fluorinated gases. *Magn Reson Med.* 2008;59(4):739–746.

137. Couch MJ, Ouriadov A, Santyr GE. Regional ventilation mapping of the rat lung using hyperpolarized (1):(29)Xe magnetic resonance imaging. *Magn Reson Med.* 2012;68(5):1623–1631.

138. Deninger AJ, Månsson S, Petersson JS, et al. Quantitative measurement of regional lung ventilation using 3He MRI. *Magn Reson Med.* 2002;48(2):223–232.